Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + CHOP for Untreated Nodal TFH Cell Lymphomas
NCT07278856Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in follicular T-cell lymphoma (FTCL), sponsored by City of Hope. Primary endpoints: Maximum Tolerated Dose and Incidence of Adverse Events. Started Dec 2025; status: recruiting.
02
Drugs
03
Conditions
follicular T-cell lymphoma (FTCL)
Beyond the preview
Go deeper on NCT07278856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07278856.